Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Short-term Investments: 2016-2024

Historic Short-term Investments for Rocket Pharmaceuticals (RCKT) over the last 8 years, with Dec 2024 value amounting to $208.7 million.

  • Rocket Pharmaceuticals' Short-term Investments fell 13.67% to $146.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.8 million, marking a year-over-year decrease of 13.67%. This contributed to the annual value of $208.7 million for FY2024, which is 34.22% down from last year.
  • Rocket Pharmaceuticals' Short-term Investments amounted to $208.7 million in FY2024, which was down 34.22% from $317.3 million recorded in FY2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Short-term Investments peaked at $317.3 million during FY2023, and registered a low of $156.0 million during FY2021.
  • Over the past 3 years, Rocket Pharmaceuticals' median Short-term Investments value was $215.9 million (recorded in 2022), while the average stood at $247.3 million.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Short-term Investments soared by 56.34% in 2020 and then slumped by 34.22% in 2024.
  • Yearly analysis of 5 years shows Rocket Pharmaceuticals' Short-term Investments stood at $185.6 million in 2020, then decreased by 15.93% to $156.0 million in 2021, then surged by 38.34% to $215.9 million in 2022, then spiked by 46.97% to $317.3 million in 2023, then plummeted by 34.22% to $208.7 million in 2024.